Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized Trial.

ABSTRACT: Previously we have shown that early development of rash is associated with a higher chance of achieving pathological complete response to neoadjuvant lapatinib. In the current analysis, we investigate its impact on survival in the ALTTO phase III adjuvant trial. In ALTTO, patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer were randomly assigned to adjuvant trastuzumab, lapatinib, their sequence, or their combination for a total duration of one year. We evaluated whether the development of early lapatinib-related rash (ie, within 6 weeks) is associated with disease-free (DFS) and overall survival (OS). Landmark analysis at eight weeks and time-dependent analysis were tested in a multivariable model stratifying on trial's stratification factors. All st

SUBMITTER: Sonnenblick A 

PROVIDER: S-EPMC5017935 | biostudies-literature | 2016 Aug

REPOSITORIES: biostudies-literature